Once the Mace parametres are better understood this quarter, the resulting lower OPEX & the impact this has on accelerating the discounted payback for the "on-site treatment case" will sharper the FS economics. The RMS bid looks opportunistic to me, and unless the USD Au price rebounds, and that is looking shaky for at least a few months (as the USD remains a safe haven until the Phoney (Trade) War resolves itself), I can see loyal EXU shareholders being duded by 5-7 cps here by end 2018.
